Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Entyvio (Vedolizumab) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2016 Dec.
- CDAI
Crohn’s Disease Activity Index
- CDR
CADTH Common Drug Review
- CI
confidence interval
- CrI
credible interval
- EMA
European Medicines Agency
- EQ-5D
EuroQol 5-Dimensions Questionnaire
- HRQoL
health-related quality of life
- IBD
inflammatory bowel disease
- IBDQ
Inflammatory Bowel Disease Questionnaire
- IDC
indirect comparison
- ITT
intention-to-treat population
- IV
intravenous
- MCID
minimal clinically important difference
- MCS
mental component summary
- MD
mean difference
- NICE
National Institute for Health and Care Excellence
- NMA
network meta-analysis
- PCS
physical component summary
- PY
patient-year
- RD
risk difference
- RR
relative risk
- SF-36
Short Form (36) Health Survey
- TNF
tumour necrosis factor
- VAS
visual analogue scale
- ABBREVIATIONS - Entyvio (Vedolizumab)ABBREVIATIONS - Entyvio (Vedolizumab)
- Homo sapiens proteasome 20S subunit beta 5 (PSMB5), transcript variant 1, mRNAHomo sapiens proteasome 20S subunit beta 5 (PSMB5), transcript variant 1, mRNAgi|1653961225|ref|NM_002797.5|Nucleotide
Your browsing activity is empty.
Activity recording is turned off.
See more...